MBX Biosciences, Inc. Common Stock Total Liabilities
MBX Biosciences, Inc. Common Stock total liabilities. Based on the latest financial reports, MBX Biosciences, Inc. Common Stock (MBX) has total liabilities worth $14.95 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MBX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of MBX Biosciences, Inc. Common Stock (2022–2025)
Total liabilities of MBX Biosciences, Inc. Common Stock from 2022 to 2025. This chart illustrates how MBX Biosciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
MBX Biosciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of MBX Biosciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Charter Hall Long Wale REIT
AU:CLW
|
Australia | AU$2.01 Billion |
|
Skyworth Digital Co Ltd
SHE:000810
|
China | CN¥4.79 Billion |
|
Dynavax Technologies Corporation
NASDAQ:DVAX
|
USA | $412.37 Million |
|
Semapa
LS:SEM
|
Portugal | €3.38 Billion |
|
BaoViet Holdings
VN:BVH
|
Vietnam | ₫281.19 Trillion |
|
CJ Cheiljedang
KO:097950
|
Korea | ₩19.20 Trillion |
|
CHINA CONCH VENT. HD -01
F:68C
|
Germany | €33.41 Billion |
|
Jiangnan Mould & Plastic Technology Co Ltd
SHE:000700
|
China | CN¥3.09 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down MBX Biosciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of MBX Biosciences, Inc. Common Stock.
Liquidity & Leverage Metrics
MBX Biosciences, Inc. Common Stock Total Liabilities Ratios Explained
MBX Biosciences, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MBX Biosciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MBX Biosciences, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of MBX Biosciences, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.92 Million | +43.52% |
| 2024-12-31 | $11.09 Million | -92.92% |
| 2023-12-31 | $156.65 Million | +78.62% |
| 2022-12-31 | $87.70 Million | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more